You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma

    SBC: Syntrix Biosystems, Inc.            Topic: 102

    The chemokine receptors CXCR1 and CXCR2 (CXCR1/2) are validated as having essential roles in the growth, survival, motility, invasion and angiogenesis of human melanoma, which secretes abundant amounts of the corresponding chemokine ligands, including CXCL8. Additionally, abnormal cancer-induced immunosuppressive myeloid-derived suppressor cells (MDSCs) in the circulation and tumor correlate with ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. An Automated Early Motor Development Risk Screener from Observational Video Recordings of Infants and Toddlers

    SBC: BSolutions Inc            Topic: NICHD

    Motor development plays a pivotal role in an infant’s overall development and has a cascading effect on social, cognitive, memory, and language ability. These functions can be compromised when motor development is disrupted; motor disruption is associated with generalized developmental delays. Early screening and identification of delays can allow early interventions with the goal of not just im ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    ABSTRACT Multiple myeloma (MM) is the second most common hematopoietic cancer and while survival rates have slowly increase in the last 10 years, the five-year survival is just over 50%. The high number of patients that become refractory to current therapies is the core reason for the low long-term survival. Therefore, there is a crucial need to develop unique drugs that are active in refractory a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Lab-To-Marketplace: Commercialization of a stretchable microelectrode array

    SBC: BMSEED LLC            Topic: 101

    Project Summary/Abstract The proposed work is directed at the commercialization of BMSEEDandapos;s Micro-Electrode Array Stretching Stimulating und Recording Equipment (MEASSuRE) technology. MEASSuRE bridges the gap between in vitro and in vivo research by simulating the biomechanical and electrical environment of cells in the body in a controlled environment outside of the body. The applications ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer

    SBC: PreCyte Inc            Topic: 102

    Project SummaryThe Indicator Cell Assay PlatformiCAPis an inexpensive blood based assay that can be used for early detection of diseasedisease stage stratificationprognosis and response to therapy for a variety of diseasesThe iCAP uses culturedstandardized cells as biosensorscapitalizing on the ability of cells to respond to disease signals present in serum with exquisite sensitivityas opposed to ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Pdot-Enabled Point-of-Care Digital PCR for Sensitive Detection of SARS-CoV-2

    SBC: LAMPROGEN INC            Topic: 400

    Project Summary Current SARS-CoV-2 molecular diagnosis tests mostly are based on real-time quantitative PCR (qPCR). Digital PCR is a next-generation PCR technology based on limiting dilution, end-point PCR, and Poisson statistics. Digital PCR transforms the exponential, analog nature of qPCR quantification into a linear, digital signal quantification. Compared to qPCR, digital PCR offers several i ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: NIEHS

    Summary Enhanced Recovery of Pharmaceutical Solvent driven by EPA InitiativeThe United States Environmental Protection AgencyEPAis establishing new safeguards for hazardous secondary materials with objectives to promote the economicenvironmentaland public health benefits of recycling wasteswith an emphasis on several industrial sectorsincluding the pharmaceutical industryOn averagepharmaceutical m ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction

    SBC: Recursion Pharmaceuticals, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Chronic diseases of aging account for a significant proportion of healthcare spending and result in a painful and limiting existence for many tens of millions of Americans and hundreds of millions of people around the world. Recursion Pharmaceuticals has developed a drug discovery platform that re-purposes known drugs for the treatment of such diseases. The pla ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease

    SBC: PreCyte Inc            Topic: NIA

    Project Summary. PreCyte is developing the Indicator Cell Assay Platform (iCAP) as a broadly applicable and inexpensive blood-based assay that can be used for the early detection of disease, disease stage stratification, prognosis and predicting response to therapy for a variety of diseases. The iCAP uses cultured, standardized cells as biosensors, capitalizing on the ability of cells to respond t ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. IOBIO based, distributed genomic data access, management, visualization, and analysis

    SBC: Frameshift Labs, Inc.            Topic: 172

    The precision medicine initiative coupled with advances in genomic research and diagnostics isleading to vast increases in the volume of genomic data being createdwith some estimates statingit will outstrip the storage requirements of YouTube byEnsuring all this data can becost effectively managedand that experts from the biomedicalinformatics and medical disciplinescan easily collaborate on analy ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government